Complete Your Assessment
Provide relevant medical and medication information.
Personalized compounded tirzepatide is a medication with activity at two hormone receptors involved in metabolic regulation: GIP and GLP-1.
Bodi Envi connects eligible patients with licensed healthcare providers who can evaluate whether an available treatment option is medically appropriate.
Some programs may involve personalized compounded tirzepatide when prescribed by a licensed healthcare provider and permitted under applicable law.
Personalized compounded tirzepatide is not FDA-approved and is not equivalent to an FDA-approved tirzepatide product. Personalized compounded tirzepatide is not regulated by the FDA; compounding pharmacies are regulated by the board of pharmacy for sterile compounding and required to follow US pharmacopeia standards.
Bodi Envi does not manufacture or compound medication.
Personalized compounded tirzepatide acts at both:
Glucose-dependent insulinotropic polypeptide, or GIP, receptors
Glucagon-like peptide-1, or GLP-1, receptors
These pathways are involved in several processes related to metabolism, appetite and glucose regulation.
This dual receptor activity distinguishes personalized compounded tirzepatide from medications that primarily act at GLP-1 receptors alone.
Personalized compounded tirzepatide activates both GIP and GLP-1 receptors.
These pathways can influence:
Appetite
Satiety
Food intake
Insulin response
Glucagon regulation
Digestion
For some patients, treatment may reduce hunger and make smaller portions feel more satisfying.
Individual responses vary.
GIP stands for glucose-dependent insulinotropic polypeptide.
It is a naturally occurring hormone involved in metabolic signaling.
Personalized compounded tirzepatide's activity at both GIP and GLP-1 receptors is one of the primary pharmacologic differences between personalized compounded tirzepatide and semaglutide.
Tirzepatide is the active ingredient in FDA-approved prescription medications for specific indications.
Different products and indications have specific prescribing information, warnings and dosing instructions.
Patients should rely on their healthcare provider and official prescribing information when considering treatment.
Personalized compounded tirzepatide is prepared by a compounding pharmacy when prescribed under applicable circumstances.
Personalized compounded tirzepatide is not FDA-approved.
It has not undergone FDA premarket review for safety, effectiveness or quality.
Personalized compounded tirzepatide should not be represented as a generic version of an FDA-approved tirzepatide product.
It is not equivalent to an FDA-approved tirzepatide product. The FDA does not regulate compounding pharmacies; the board of pharmacy for sterile compounding regulates compounding pharmacies.
Bodi Envi does not manufacture or compound tirzepatide.
A licensed healthcare provider determines whether a treatment option is appropriate for the patient.
The evaluation may include:
Medical history
Current medications
Weight history
Body mass index
Weight-related medical conditions
Previous treatment
Potential contraindications
Pregnancy status
Individual goals
Completing an assessment does not guarantee treatment. If a patient is not qualified, a full refund is issued.
Personalized compounded tirzepatide can cause side effects.
Common gastrointestinal effects reported include:
Nausea
Diarrhea
Vomiting
Constipation
Abdominal discomfort
Other adverse effects may occur.
Patients should review potential risks and warnings with their healthcare provider.
Learn More About Side Effects or read our Medication Safety page.
A prescribing healthcare provider determines the appropriate treatment and dosing plan.
Patients should follow their prescribed instructions and should not increase their dose independently.
Dose changes may depend on treatment response, tolerability and the provider's clinical judgment.
Reduced appetite can change eating patterns.
Maintaining adequate protein, fluids, fiber and overall nutrition remains important during medical weight management.
Physical activity remains an important part of overall health.
Resistance training may be particularly useful when appropriate for helping support muscle and physical function during weight loss.
Personalized Compounded Tirzepatide programs through Bodi Envi are $175 to $229 per month based on plan. The price is the same at every dose.
Pricing includes:
Provider evaluation
Medication
Supplies
Shipping
Ongoing provider access
Patient support
Dose changes
GLP-1 ebook and diet plan
Provide relevant medical and medication information.
A healthcare provider evaluates your information.
The provider determines whether treatment is appropriate.
When prescribed, medication is dispensed by VialsRx, a 503A licensed pharmacy.
Patients have access to appropriate follow-up and treatment monitoring.
Personalized compounded tirzepatide has activity at both GIP and GLP-1 receptors and is often discussed alongside GLP-1 medications.
No. Compounded medications are not reviewed by the FDA. Compounding pharmacies are regulated by the board of pharmacy for sterile compounding.
No. Personalized compounded tirzepatide should not be described as a generic version of an FDA-approved tirzepatide product.
There is no treatment that is automatically best for every patient. The medications have different pharmacology, and a healthcare provider should consider the individual patient's medical circumstances.
No. Bodi Envi does not manufacture or compound medication.
Explore more about GLP-1 medications and how treatment works:
Complete a secure online health assessment for review by a licensed healthcare provider.